02 — Bay-Area / US Bio-Startup Scene (Organ Sacs + Reprogramming + Regen + DIY Gene Therapy)

Landscape doc for the 2026 biohacking map. Web-search verified 2026-05-31. Cross-links: /workspace/health/organ-sacs/ (deep dive on bodyoids) and /workspace/health/longevity/ (author profiles + intervention evidence). Every factual claim carries a source URL; load-bearing numbers get 2 sources where possible. Demonstrated-vs-speculative is marked throughout. Confidence tiers C1–C5 per /workspace/RESEARCH-BEST-PRACTICES.md §6.

TL;DR (read this first)

1. The money is real; the products mostly aren't. Cellular-reprogramming longevity has soaked up the largest biotech bets in history — Altos Labs ($3B), Retro Biosciences (~$1B Series A, $1.8B valuation May 2026), NewLimit ($280M) — yet as of mid-2026 none has an approved age-reversal therapy and almost all human data is still pending or in early safety trials.
2. Where there's actual clinical data, it's narrow disease indications, not "aging." Retro's first trial is an Alzheimer's protein-clearance pill; Unity's senolytic has Phase 2b eye-disease data; Calico's headline aging drug failed in ALS and AbbVie walked. The "cure aging" framing runs far ahead of the regulatory reality (single-disease endpoints).
3. Regenerative/organ engineering is further along than reprogramming for the "biopunk-2037" goal. Xenotransplant pig organs are in FDA-cleared human trials (eGenesis, United Therapeutics); United's miroliverELAP (ex-Miromatrix) hit its Phase 1 endpoint Jan 2026; LyGenesis is growing ectopic mini-livers in lymph nodes in a Phase 2a. These are demonstrated in humans, unlike organ sacs.
4. The DIY / self-experimentation fringe persists but has a body count and no rigor. Liz Parrish (BioViva) and Minicircle (follistatin, ~$25k, in Próspera/Honduras, tried by Bryan Johnson) have published no rigorous clinical trial data; Aaron Traywick (Ascendance) died in 2018. The charter-city venue (Próspera; Vitalia's 2024 pop-up split in Jan 2025 into Infinita City + Viva City) is itself legally precarious.
5. Organ sacs / bodyoids (R3 Bio, Kind Bio) are the least-developed, highest-ethical-burden node — no organ sac exists; see the dedicated folder. They sit closest to end-goal #2 conceptually but furthest from demonstration.
6. Honest skeptic read: reprogramming = real science + serious cancer-risk and "is-this-just-iPSC" problems + heavy hype; xeno/regen = real clinical progress; DIY gene therapy = mostly grift/theater with genuine danger; organ sacs = speculative moonshot. Follow the disease endpoints, not the press.

0. How this connects to the two end-goals

• End-goal #1 (mind-uploading / substrate independence): this scene is mostly orthogonal — none of these companies touch connectomics or emulation (that's doc 03/04). The one bridge is Jean Hébert's ARPA-H brain-tissue-replacement program (covered in organ-sacs) + the "body, brain" pairing: organ sacs would give a brain somewhere to go. Relevant but indirect.
• End-goal #2 (biopunk-2037: grown organs, body cultivation, nerve reconnection): this is the core doc. The realistic 2026 substrate for biopunk-2037 is xenotransplant + bioengineered/ decellularized organs + ectopic organ growth, not organ sacs and not reprogramming. See §6 closing.

1. Organ sacs / bodyoids — recap + cross-link (brief)

Full treatment: organ-sacs/research/landscape-overview.md. One-paragraph summary for the map:

R3 Bio (Richmond, CA; John Schloendorn / Alice Gilman) and Kind Biotechnology (NH; Justin Rebo, George Church advising) are pursuing "organ sacs"/"bodyoids" — brainless bodies grown for organs / drug testing / (privately pitched) full-body replacement. Demonstrated: nothing resembling an organ sac. Closest evidence is Kind Bio patent images of gene-knockout mice lacking complete brains/faces/limbs; R3 has no published research. Funding is small longevity-moonshot money (Tim Draper; Immortal Dragons $500K; LongGame). MIT Tech Review (Mar 30 2026) exposed R3's private "brainless human clones" pitch at a $70k Diamandis event. Skeptic take: valid underlying science (gene knockout), enormous gap to the pitch, very high ethical burden, decades away if ever. The artificial-womb bottleneck (no human ectogenesis exists) is fatal to the near-term human story. organ-sacs landscape · C1 (internal, web-verified Apr 2026)

Adjacent academic node also covered there: Hiromitsu Nakauchi (Stanford, blastocyst complementation / human-pig chimeric organs), Renewal Bio (Jacob Hanna, synthetic embryo models, Israel), Michael Levin (Tufts, bioelectricity/xenobots), Jonathan Slack (1997 headless frog embryos), and the Charlesworth/Greely/Nakauchi 2025 "bodyoid" concept paper.

2. Cellular / partial reprogramming longevity companies

The dominant Silicon-Valley longevity thesis: transiently express Yamanaka factors (OSK/OSKM) to "reset" the epigenetic age of cells without turning them back into stem cells (full iPSC). For the underlying science and the Sinclair/Brenner debate, see longevity/master-list.md (Yamanaka, Sinclair, Horvath, Brenner) and the planned longevity/research/great-debates.md. This section maps the companies.

2A. Altos Labs (San Francisco / San Diego / Cambridge UK)

• Claim/funding: Launched 2022 with $3B initial funding — the largest biotech launch ever — backed by Jeff Bezos, Yuri Milner, and ARCH Venture Partners. C1/C2 · Fight Aging! May 2026, longevity.technology
• Science / people: Built around Nobel laureate Shinya Yamanaka (unpaid senior advisor) + Juan Carlos Izpisúa Belmonte; recruited Steve Horvath, Morgan Levine, Thomas Rando, etc. (see longevity profiles). Approach: partial epigenetic reprogramming to restore cellular health.
• Demonstrated: Benefits in mouse models (lifespan/healthspan); reportedly began early human safety testing in Aug 2025; ex vivo organ reprogramming work (e.g. rejuvenating aged kidneys for transplant) reported. No approved therapy; clinical data not yet public. C3 (secondary reports, not company primary) · longevity.technology
• 2026 signal: Appointed Joan Mannick (ex-resTORbio/Life Biosciences) as CMO/head of product, read as a pivot toward clinical programs. C2 · longevity.technology
• Skeptic take: Spectacular funding, world-class team, still essentially pre-clinical in humans 4 years in. Reprogramming's cancer/teratoma risk (see §2H) is the central unsolved problem. Hype ratio high relative to public data.

2B. Retro Biosciences (San Francisco / Redwood City)

• Claim/funding: Founded ~2021; Sam Altman put in $180M personally; raised a ~$1B Series A in early 2025; $1.8B valuation confirmed May 22 2026. Mission: "add 10 healthy years." C1/C2 · STAT, May 22 2026, TechCrunch/TechStory on $180M, WebProNews $1B
• People: CEO Joe Betts-LaCroix (YC-backed; see longevity profile).
• Demonstrated (best real-clinical data in this section): Running its first clinical trial — an oral pill to enhance clearance of protein aggregates in Alzheimer's patients. Betts-LaCroix (STAT Breakthrough Summit West, May 2026): trial going "super good," no dose-limiting toxicities, data expected ~Aug 2026. Programs span in-vivo gene therapy, cell-replacement, reprogramming. C2 · STAT, webpronews Alzheimer's
• Notable: Aug 2025, with OpenAI, reported AI models that made reprogramming ~50× more efficient (company/OpenAI claim, not independently peer-reviewed). C4 · STAT
• Skeptic take: The fact that the actual trial is a narrow Alzheimer's protein-clearance pill — not "reversing aging" — is the tell: even the best-funded reprogramming-adjacent shop monetizes via a conventional single-disease endpoint. Valuation is AI-halo-inflated.

2C. NewLimit (San Francisco)

• Claim/funding: Co-founded by Coinbase CEO Brian Armstrong (+ Blake Byers, Jacob Kimmel). $130M Series B (May 2025, led by Kleiner Perkins, ~$810M valuation); Eli Lilly invested $45M (Oct 2025) pushing total funding >$280M and valuation ~$1.62B. C1/C2 · TechCrunch, medpath, thepeptidelist on $280M/Lilly
• Demonstrated (most concrete preclinical reprogramming data here): Jan 2026 — reprogrammed hepatocytes from a donor >60 began expressing genes of cells "decades younger," with increased resistance to alcohol damage and improved regenerative capacity; AI system "Ambrosia"; tested >3,000 transcription-factor combos, screened >50 payloads, identified 4 candidate biomarkers; also a T-cell rejuvenation program (19 payloads). C2 · longevity.technology
• Timeline: Human clinical trials projected ~2028 (company guidance). C3 · longevity.technology
• Skeptic take: The most transparent of the reprogramming cos about its actual data (in-vitro human cell results, not just mouse). But still in vitro / preclinical, and Eli Lilly's buy-in is the more meaningful validation signal than the crypto-founder branding.

2D. Calico (Calico Life Sciences — South San Francisco, Alphabet/Google)

• Status: Founded 2013 with Alphabet + AbbVie backing (AbbVie put in ~$2.5B+ over the partnership). AbbVie terminated the 11-year collaboration (Nov 2025) after fosigotifator failed a Phase II/III ALS trial; ~100 staff laid off. C1/C2 · FierceBiotech, STAT Jan 2025
• Pipeline: ~5 candidates in clinic, ~20 preclinical, hundreds of papers; June 2025 licensed an anti-IL-11 drug (extends mouse lifespan 22–25%) for $25M upfront + up to $571M milestones. C2 · Nature, Wikipedia/Calico
• Skeptic take: The cautionary tale of the section — ~$3.5B and a decade in, the flagship "aging" asset failed in its disease trial and its pharma partner exited. Calico is not a reprogramming play (it's target-discovery/geroscience), and is "going it alone." Evidence that money ≠ outcomes here.

2E. Turn Biotechnologies (Mountain View, CA)

• Approach: mRNA-based "ERA" (Epigenetic Reprogramming of Aging) partial reprogramming; lead programs in dermatology/ophthalmology/immunology.
• Funding: Total ~$30.1M over 4 rounds (Tracxn). C3 · Tracxn (NB: do not confuse with "Turn Therapeutics," an unrelated topical-pharma SEC filer.)
• Demonstrated: Preclinical. No approved product, no late-stage human data found. C3
• Skeptic take: Small relative to the headline trio; betting on local (tissue-specific) reprogramming to sidestep systemic cancer risk. Real approach, early stage.

2F. Shift Bioscience (Cambridge, UK — included for completeness)

• Approach: AI "virtual cell" / single-cell aging-clock models to find safe rejuvenation genes (decouple rejuvenation from de-differentiation). $16M seed (funds through ~2026). C2 · longevity.technology
• Skeptic take: Explicitly targets the safety hole others gloss over; preclinical; small. Not Bay-Area but central to the reprogramming-safety conversation.

2G. Unity Biotechnology & Gordian Biotechnology (senolytics, not reprogramming — adjacent)

• Unity (South San Francisco): Founded by Nathaniel David / Ned David (see longevity profiles), early backers incl. ARCH, Fidelity, Bezos, Thiel-adjacent. Lead asset UBX1325 (foselutoclax) — a BCL-xL inhibitor senolytic for diabetic macular edema (DME). Phase 2b ASPIRE (2025/26): ~+5.5 letter vision gain at weeks 24/36; achieved non-inferiority to aflibercept at 9/10 timepoints (missed one primary CI threshold). C1/C2 · Unity IR ASPIRE, StockTitan
• Gordian Biotechnology (SF): Pooled in-vivo screening ("mosaic" organs, barcoded therapies at low dose, thousands of targets per animal) for HFpEF, osteoarthritis, pulmonary fibrosis. Tooling company, not a senolytic-product company per se. C3 · Gordian, workinbiotech
• Skeptic take: Senolytics (clearing senescent cells) is a different, more mature longevity bet than reprogramming; Unity is the rare one with real Phase 2b human efficacy data — but in DME (an eye disease), again not "aging." History: Unity's earlier osteoarthritis senolytic (UBX0101) failed Phase 2 in 2020, tanking the stock — a documented hype-to-reality correction.

2H. Life Biosciences (Boston — David Sinclair's reprogramming co; the clinically most advanced OSK story)

• Why it matters: Co-founded by David Sinclair, Life Biosciences runs a Partial Epigenetic Reprogramming (PER) platform expressing three Yamanaka factors (OSK: OCT4, SOX2, KLF4) — and it is arguably further along the regulatory path than Altos/Retro/NewLimit, which is why its omission was a gap. Lead asset ER-100 for optic neuropathies.
• Demonstrated: Non-human-primate data in a NAION-like optic-nerve injury model showed restored DNA-methylation patterns and functional neuronal-regeneration signatures after a single intravitreal dose (+ systemic doxycycline to gate expression). FDA cleared the ER-100 IND on Jan 28 2026 — billed as the first epigenetic-reprogramming / cellular-rejuvenation therapy cleared to enter human trials — with first-in-human dosing slated for Q1 2026. Demonstrated (primate) → entering clinical. C2 · Life Biosciences: ER-100 IND clearance, Lifespan.io: first human cellular-reprogramming trial cleared, Ophthalmology Times (primate data)
• Skeptic take: This is the first OSK reprogramming therapy to clear an FDA IND — directly relevant to Brenner's "won't clear an IRB" skepticism in §2H-below (it did, for a localized eye indication via intravitreal delivery with a doxycycline on-switch — i.e. it sidesteps the systemic cancer-risk problem rather than solving it). A genuine milestone, but still a narrow, locally-delivered indication, not systemic age reversal. The Niche/ipscell flags it as "risky, pioneering." C2 · The Niche/ipscell, Feb 2026

2I. The reprogramming skeptic case (load-bearing)

• Charles Brenner ("the longevity skeptic," City of Hope) argues partial reprogramming is "in its infancy," that the cancer/tumor risk is real and under-disclosed, and that the trick (get "younger" cells of the same fate, not iPSCs or "neoplastic intermediates like aggressive neural precursors") is unsolved. He doubts naked OSK gene therapy will clear an IRB into trials. C2 · The Niche/ipscell, longevity.technology
• Fight Aging! (pro-longevity but technical) flags ongoing "partial reprogramming concern" and remaining challenges as of 2026 — i.e. even advocates concede it's unproven. C3 · Fight Aging! Apr 2026
• Bottom line: The science (Yamanaka factors transiently rejuvenate cells/mice) is genuine; the leap to a safe, systemic human therapy that doesn't cause cancer is not yet made by anyone. Treat all "age reversal" company framing as aspiration until a controlled human trial with hard endpoints reports.

3. Regenerative / organ engineering (closest to biopunk-2037, most real clinical data)

3A. Miromatrix → United Therapeutics (decellularized/recellularized organs)

• History: Miromatrix (Univ. of Minnesota spinout; decellularize a pig organ to an ECM "scaffold," reseed with human cells) was acquired by United Therapeutics for ~$91M (Oct/Dec 2023). C1/C2 · UMN, FierceBiotech (Note: the prompt's "Reprise/UHN" — I could not confirm a Reprise or University Health Network tie to Miromatrix; the acquirer is United Therapeutics. Flagged as unverified — see §8.)
• Demonstrated (real human data): miroliverELAP (external liver-assist device) hit its Phase 1 primary endpoint — 5 acute-liver-failure patients (non-transplant-candidates) treated ≥44h, all survived during treatment, no unexpected serious adverse events over 32-day follow-up (announced Jan 26 2026); Phase 2 planned, full results 2H2026. C1/C2 · United Therapeutics PR (PDF), INN
• Goal: Fully bioengineered transplantable kidneys/livers (MiroKidney/MiroLiver), longer-term.
• Connects to: biopunk-2037 organ-cultivation directly — lab-built organs from scaffolds, a more incremental path than organ sacs.

3B. LyGenesis (Pittsburgh — ectopic organ growth)

• Approach: Inject donor hepatocytes via endoscopic ultrasound into a patient's upper-abdominal lymph nodes, which act as in-vivo bioreactors growing miniature ectopic livers.
• Demonstrated (in humans): Phase 2a for end-stage liver disease — first patient dosed Apr 2024, 12-patient target; DSMB approved continuation + dose escalation (Mar 2025). C1/C2 · LyGenesis PR, Applied Clinical Trials
• Skeptic take: Genuinely novel, genuinely in humans, but early (Phase 2a, small N); ectopic mini-livers ≠ a full replacement organ. Among the more credible "grow-an-organ" plays.
• Connects to: biopunk-2037 — growing functional organ tissue inside a living person.

3C. Xenotransplantation — pig organs (most clinically advanced of all)

Detailed in organ-sacs landscape §6A. 2026 status:

• eGenesis (Cambridge, MA): EGEN-2784, a 69-edit / 3-class-modification pig kidney (3 glycan knockouts, 7 human transgenes, PERV inactivation). FDA IND clearance (Sep 2025) for a combined Phase 1/2/3; second human transplant successful Jan 25 2026 (patient discharged, off dialysis). C1/C2 · Inside Precision Medicine, FierceBiotech
• United Therapeutics / Revivicor: UKidney (10-gene-edited pig kidney); FDA-approved trial (EXPAND, NCT06878560), first transplants 2025–26; building a ~$110M pathogen-free pig facility (Stewartville, MN). CEO Martine Rothblatt envisions industrial-scale "manufactured organs." C1/C2 · NYU Langone, organ-sacs landscape
• Skeptic take: This is the real, FDA-blessed, in-human path to engineered organ supply. Caveats: imperfect immune match (still needs immunosuppression), PERV risk, individual organs only (no whole body). But it is years ahead of organ sacs and arguably the true 2026 substrate for biopunk-2037's "replacement organs."
• United Therapeutics is the connective hub here: it owns Revivicor (xeno), bought Miromatrix (bioengineered organs), and is the same company behind several of these programs — the most serious industrial organ-manufacturing bet in the US.

3D. Artificial wombs (the bodyoid + neonatal bottleneck)

• EXTEND (CHOP — Children's Hospital of Philadelphia): "Extra-uterine Environment for Newborn Development." 2017: kept a premature lamb alive ~28 days in a fluid-filled bag (umbilical oxygenation, lung/GI/brain growth). Commercialized via Vitara Biomedical (Philadelphia), ~$100M raised. C1/C2 · CHOP, Scientific American
• FDA: Pediatric Advisory Committee held an ethics/feasibility hearing (Sep 2023; further review 2025) on first-in-human trials. Target use is extremely premature infants (~22–24wk), i.e. partial ectogenesis. C2 · Scientific American
• Crucial caveat for biopunk-2037 / bodyoids: EXTEND supports an already-developed late fetus. Full ectogenesis (embryo → term outside a body) does not exist and is likely decades away. This is the hard bottleneck that makes human organ sacs implausible near-term (see organ-sacs §8).

4. DIY / self-experimentation gene therapy (the "biohacker" fringe)

This is where "biohacker identity" meets actual gene therapy — and where rigor collapses.

4A. Liz Parrish / BioViva (Bainbridge Island, WA)

• What happened: CEO Parrish became "patient zero" in 2015 (age 44), self-administering AAV telomerase (hTERT) + follistatin gene therapy outside the US (Colombia). C1/C2 · Wikipedia/BioViva, Longevity World Forum
• Demonstrated: A single-subject case report (n=1, herself) reporting telomere lengthening and no treatment-related complications over ~5.8 years. This is anecdote, not a trial. Now also pursuing klotho. George Church has shown BioViva data in talks (2024). C4 (n=1, self-reported) · Longevity World Forum, Medium/Tim Ventura Apr 2026
• Skeptic take: Telomerase gene therapy has a plausible animal basis (Blasco's 2012 mouse AAV-TERT work increased mouse lifespan w/o raising cancer) but n=1 in a CEO with obvious incentives is not evidence. Long-running cancer-risk concern (telomerase is upregulated in most cancers). Genuine-belief fringe, not fraud, but not science.

4B. Minicircle (Próspera, Honduras) — follistatin gene therapy

• What: Plasmid ("minicircle") follistatin gene therapy (follistatin suppresses myostatin → muscle growth; longevity claims). Sold to the public at the GARM clinic in Próspera for a reported ~$25,000. C1/C2 · MIT Tech Review Dec 22 2025, ScreenRant/Don't Die
• Bryan Johnson: Took it; self-reported muscle mass +7%, follistatin +160% (promoted in the Netflix Don't Die documentary). C2/C4 (self-report) · Tortoise, Bloomberg
• Demonstrated: No rigorous clinical trial data published. MIT Tech Review (Dec 2025) and experts (Seppo Ylä-Herttuala) note evidence is mostly rodent, and there's "even less data" on follistatin than on comparable VEGF therapies. Operates outside FDA oversight under Próspera's bespoke regime. C2 · MIT Tech Review
• Skeptic take: A real intervention with a plausible mechanism, sold to consumers before any controlled human efficacy/safety data exists, in a jurisdiction chosen to avoid the FDA. The Bryan Johnson involvement is marketing. Buyer-beware territory. (Note: Immortal Dragons' Boyang Wang — an R3 Bio investor — was among Minicircle's first ~300 follistatin recipients; the longevity-investor network overlaps heavily, per organ-sacs landscape §7A.)

4C. The charter-city / medical-tourism venue: Próspera → Vitalia → Infinita

• Próspera ZEDE (Roatán, Honduras): pro-tech special economic zone; physical clinical hub is the GARM clinic. Hosted Vitalia — a longevity pop-up city ("make death optional") that ran a major ~2-month pop-up in 2024 (the headline Jul 2024 gathering, attended by Bryan Johnson and Balaji Srinivasan), with a follow-on pop-up running into early 2025 (through ~Mar 3 2025). In January 2025 the co-founders split: Niklas Anzinger kept the permanent Roatán hub and renamed it "Infinita City" (March 2025; permanent biomedical network city, regulatory-acceleration focus; raised ~$3M), while Laurence Ion left to start "Viva City" (a separate resident-governed longevity-city project, based out of San Francisco). So the clean story is: Vitalia (2024 pop-up) → Jan 2025 founder split → Infinita City (Anzinger) + Viva City (Ion). C2 · New Republic, Lifespan.io: Vitalia co-founders announce split-up, Infinita City (X, Jan 2025: "From Vitalia to Infinita"), Pharmaceutical Technology
• Legal precarity: Honduras repealed the ZEDE law (2022) and its Supreme Court ruled ZEDEs unconstitutional (Sep 2024, retroactive); Próspera is in an ~$10.7B investor-state arbitration against Honduras. Existing operations continue pending the dispute, but the long-term legal basis is contested. C2 · Wikipedia/Próspera, Dentons
• Skeptic take: This is the institutional engine of "regulatory-arbitrage biotech" — gene-therapy cocktails sold to longevity tourists outside FDA reach. Mixed: real experimentation + real lack of oversight + a legally shaky host jurisdiction. Boing Boing and others framed Vitalia's 2025 split as a "collapse"; more precisely, it rebranded and shrank amid the ZEDE legal crisis. C3/C4 · Boing Boing

4D. Aaron Traywick / Ascendance Biomedical (history / cautionary tale)

• What: Founded Ascendance Biomedical (2017, DC); no science background. Livestreamed a colleague (Tristan Roberts) self-injecting an untested DIY HIV gene therapy (Oct 2017; viral load rose); then Traywick self-injected a DIY herpes gene therapy on stage (Feb 2018). Found dead in a sensory- deprivation tank, age 28, Apr 29 2018 (not directly attributed to the therapy). FDA issued a warning on DIY gene editing afterward. C1/C2 · Wikipedia, MIT Tech Review, TIME
• Skeptic take: The clearest "grift-meets-danger" episode in DIY gene therapy; a documented harm node (ineffective therapy + a dead 28-year-old) the scene tends to forget. Important for an honest map.

4E. The rigorous counterpoint: APPROVED & clinical-stage human gene editing

The DIY fringe above (§4A–4D) is what gene editing looks like with no rigor. This is what it looks like with rigor — the demonstrated, regulated benchmark that makes Zayner/Parrish/Minicircle's self-injection theater look like the fringe it is. (All demonstrated/approved unless noted.)

• Casgevy (exa-cel / exagamglogene autotemcel) — first FDA-approved CRISPR therapy. CRISPR Therapeutics + Vertex; FDA-approved Dec 8 2023 for sickle-cell disease (and shortly after for transfusion-dependent beta-thalassemia) in patients ≥12. Ex vivo: a patient's own stem cells are CRISPR-edited (to reactivate fetal hemoglobin) and re-infused. This is the single most important demonstrated, approved gene-editing milestone — a one-time functional cure. Demonstrated/approved. C1 · Vertex/CRISPR Therapeutics PR, STAT, Dec 8 2023
• Lyfgenia (lovotibeglogene autotemcel) — bluebird bio. Approved the same day (Dec 8 2023) for sickle-cell; not CRISPR but a lentiviral gene-addition therapy (also ex vivo). The two approvals together opened the regulated gene-therapy era for hemoglobinopathies. Demonstrated/approved. C1 · Big Molecule Watch
• In-vivo editing — Intellia Therapeutics. The harder frontier: edit genes inside the body. Nex-z (nexiguran ziclumeran, formerly NTLA-2001) — a single-IV CRISPR therapy that knocks out the liver TTR gene for transthyretin amyloidosis — is in Phase 3 (MAGNITUDE / MAGNITUDE-2). Lonvo-z (NTLA-2002) for hereditary angioedema posted positive Phase 3 (HAELO) topline data, with a rolling BLA underway and a planned US launch ~1H 2027. Demonstrated in-human (clinical-stage), not yet approved. C2 · Intellia Q1 2026 results, CRISPR Medicine: first in-vivo CRISPR data (Caveat: a patient death was reported in an Intellia program — in-vivo editing is not risk-free; see Inside Precision Medicine.)
• Base editing — Beam Therapeutics & Verve. Base editing (single-letter DNA rewriting, no double-strand break) is the next-generation tool. Verve Therapeutics' in-vivo base editor VERVE-102 permanently inactivates liver PCSK9 to lower LDL cholesterol; a Phase 1b readout (Apr 2025) showed mean LDL-C reductions ≥50% from a single infusion — and Eli Lilly acquired Verve for ~$1.3B (deal announced Jun 2025, closed Q3 2025), a pharma vote of confidence in cardiovascular base editing. Beam Therapeutics runs its own base-editing pipeline (sickle-cell, liver disease). Demonstrated in-human (clinical-stage). C2 · Lilly: acquire Verve, BioPharm Int'l: VERVE-102 Phase 1 data
• Skeptic take / framing: This is the demonstrated benchmark. Casgevy/Lyfgenia are approved; Intellia/Verve/Beam have real in-human data under IND/regulatory oversight — multi-year trials, DSMBs, manufacturing controls, and (for Casgevy) a ~$2M+ price tag reflecting the cost of doing it properly. The contrast with §4A–4D is the whole point: self-injecting unvetted AAV/plasmid constructs in Honduras is not "the same thing, just faster" — it skips exactly the rigor that turns gene editing from theater into medicine. (Relevance to the two end-goals: this is the toolset that any future "edit the body to accept new organs / reconnect tissue" biopunk-2037 step would actually be built on.)

5. Synthetic biology / community labs / iGEM (the "biohacker" cultural base)

Brief, since doc 01 (grinder/DIY) covers the body-mod side. The wet-lab DIY-bio scene:

• Josiah/Jo Zayner & The ODIN (Oakland, CA): Ex-NASA Ames; founded The ODIN (2016) selling DIY CRISPR kits to the public; famously self-injected CRISPR (myostatin) on stage (2017). The most visible "biohacker-next-door." C1/C2 · Wikipedia/Jo Zayner, The ODIN press
• Community labs: Genspace (NYC), BioCurious (Silicon Valley), Counter Culture Labs (Oakland) — membership wet-labs that anchor the DIY-bio identity; mostly education / amateur synbio, not therapeutics. C2 · PMC: governing nonconventional genetic experimentation
• iGEM: Intl. Genetically Engineered Machine competition — the student/amateur synbio onramp; relevant as the talent pipeline and cultural identity layer ("we can engineer life") rather than as a startup node. (General knowledge — C5 for any 2025/26 specifics; not separately verified here.)
• Connection to end-goals: Mostly cultural/identity — the belief that biology is hackable. Materially, community labs do not move either end-goal forward, but they're the recruiting ground and ideology source for the people who later staff or found the startups above.

6. Synthesis: maturity map + connection to the two end-goals

Maturity ladder (most→least demonstrated in humans), mid-2026:

Connections to the two end-goals:

• End-goal #1 (uploading / substrate independence): This whole scene is largely irrelevant to uploading itself. The only structural bridge is the organ-sac ↔ ARPA-H brain-replacement pairing (a body to receive a (re)built brain) — and that's the most speculative node. If you want a body for a preserved/uploaded-then-re-embodied mind, the realistic 2026 substrate is xeno + bioengineered organs, not organ sacs. Net: watch doc 03 (BCI) and 04 (WBE) for the real path; this doc supplies the eventual "what do you put the mind back into" answer, decades out.
• End-goal #2 (biopunk-2037: grown organs / cultivated bodies / nerve reconnection): This doc is the spine of biopunk-2037. The honest 2026 read: the path runs through xenotransplant + decellularized/ bioengineered organs + ectopic organ growth (real, clinical) — not through organ sacs (concept) or reprogramming (a healthspan play, not an organ-supply play). Nerve reconnection is not addressed by a Bay-bio organ company here — but it is not an empty field (an earlier draft wrongly called it unaddressed): the strongest real evidence sits in the BCI / spinal-stimulation world — Grégoire Courtine & Jocelyne Bloch's "digital bridge" (EPFL/CHUV; ONWARD Medical), which restored thought- controlled natural walking in a chronically paralyzed human and showed neurological recovery persisting even with the system off (suggesting new nerve connections formed), published in Nature, 24 May 2023. That is demonstrated in a human — see doc 03 and doc 08. So the author's biopunk-2037 worldbuilding is directionally supported by 2026 evidence on the organ-supply axis, undercut on the full-body and artificial-womb axes (no human ectogenesis), and partially supported on nerve reconnection (a demonstrated brain–spine bridge exists; restoring an arbitrary severed peripheral nerve at scale is still unsolved). C1 · Nature 2023 (PubMed), EPFL/NeuroRestore, Science/AAAS coverage

7. Funding/investor cross-cutting note

Two overlapping money circles power this scene: - Big-tech longevity whales: Bezos + Milner (Altos $3B), Altman (Retro $180M personal / ~$1B round), Armstrong (NewLimit), Alphabet (Calico). These are fortune-scale bets on reprogramming/geroscience. - The small longevity-moonshot network (organ sacs, DIY): Tim Draper, Immortal Dragons (Boyang Wang), LongGame, Methuselah, LEV/SENS, Diamandis's Abundance events, VitaDAO (DeSci). Tightly interconnected; small checks ($100k–$1M) on high-concept bets. Same names recur (Wang funds R3 and took Minicircle's follistatin). See organ-sacs landscape §7. - Sovereign / philanthropic megafunder — Hevolution Foundation (Riyadh, Saudi Arabia): the single biggest absence if you only count the US whales. Created by Saudi royal decree (~2021) with a stated commitment of up to ~$1B/year for healthspan/geroscience research — among the largest dedicated longevity funders on earth. It is mostly a grant-maker (>$400M deployed in its first ~20 months; $230M flagship GROProgram for aging-biology preclinical work; backs the XPRIZE Healthspan with $40M; set up a Boston office), not a startup, so it shapes the field's funding base rather than any one company. C2 · Boston Globe, MIT Technology Review, Al Arabiya, Feb 2025 - Pharma validation, when it appears, is the more meaningful signal: Eli Lilly → NewLimit ($45M) and Eli Lilly → Verve (~$1.3B acquisition, §4E), AbbVie → Calico (exited), United Therapeutics (acquirer/operator across xeno + bioengineered).

8. What I couldn't verify / open questions (C5 + flags)

1. "Reprise / UHN" tie to Miromatrix (from the prompt): Could not confirm. Miromatrix was acquired by United Therapeutics (~$91M, 2023); I found no "Reprise" entity or University Health Network link. The prompt may be conflating with another company or a renamed program. Flagged — treat as unverified.
2. Altos human-trial specifics: "Began human safety testing Aug 2025" comes from secondary (longevity.technology) sources, not an Altos primary filing/registry — could not find a ClinicalTrials.gov registration to corroborate. C3.
3. Retro's $1B Series A and $180M Altman figures: Widely reported secondhand; the $1.8B valuation has a primary-grade STAT source (May 2026), but I did not see Retro's own press release for the $1B round — C2.
4. Minicircle treatment counts / outcomes: No published n, no efficacy/safety data — the "first ~300 recipients" figure traces to organ-sacs sourcing on Boyang Wang, not a Minicircle disclosure. C4.
5. iGEM / community-lab 2025–26 specifics: Not separately web-verified this pass (C5). The cultural role is well-established; current-year details are not.
6. NewLimit's in-vitro hepatocyte result is from longevity.technology reporting on company data, not a peer-reviewed paper I located — C2/C3; the headline "decades younger" is the company's framing.
7. Whether any reprogramming company has a registered, controlled human aging trial (vs. a single disease indication): I found none as of 2026 — consistent with Brenner's IRB skepticism. Worth a targeted ClinicalTrials.gov sweep before the webapp.
8. Gordian Biotechnology current funding/stage: only general (workinbiotech/Crunchbase) — not a load-bearing number here, left at C3.

Failed/weak search terms: "Reprise Biotechnologies Miromatrix UHN", "iGEM 2025 results biohacker identity", "Altos Labs ClinicalTrials.gov 2025."